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Proteoglycans: cell biologists have had a love-hate rela-
 
tionship with these molecules almost since their discov-
ery. Their biochemical properties, dominated by hetero-
 
geneous and highly charged glycosaminoglycan (GAG)
 
1
 
chains, can make purification challenging and structural
analysis painful. Their ability to bind scores of growth fac-
tors, growth factor-binding proteins, extracellular pro-
teases, protease inhibitors, extracellular matrix molecules,
and other proteins takes the concept of molecular promis-
cuity to new heights. On top of this, they seem always to
be underfoot, showing up on plasma membranes in hun-
dreds of thousands of copies per cell and in extracellular
matrices at milligram per milliliter concentrations.
And yet despite these peculiarities (or perhaps because
of them) proteoglycans have inspired an extraordinary
range of models, theories, and speculation. Since the
1960s, proteoglycans have been credited, in one system or
another, with controlling the following: cell division, adhe-
sion, spreading, migration, chemoattraction, axon guid-
ance, matrix assembly, lipoprotein uptake, extracellular
proteolysis, and viral entry.
Do proteoglycans do all of these things? Progress on this
question during the past decade has been recently kicked
into high gear by a flurry of in vivo results (in mice, frogs,
flies, and worms), in many cases coming from investiga-
tors who never intended to become involved with such dif-
ficult molecules. Here, we review some of these findings
and discuss how they both confirm old notions of pro-
teoglycan function and suggest new ones. We have chosen
to focus exclusively on the heparan sulfate proteoglycans
(HSPGs), in part because new data on these molecules
have been particularly plentiful, but mostly because those
data speak more directly about the functions of GAGs, the
moieties that make proteoglycans unique. However, it
should be noted that in vivo studies of proteoglycans that
primarily bear chondroitin/dermatan sulfate and keratan
sulfate (the other families of GAG) are also providing im-
portant new insights (Fässler et al., 1994; Danielson et al.,
1997; Olsen, 1997; Chakravarti et al., 1998).
 
The Nature of the Problem
 
To be sure, answers coming from the genetic manipulation
of animals are enriching almost all areas of biology these
days. In part, what is different about proteoglycans is that
the cell biological tools one can use to study their func-
tions, in particular the functions of their GAG chains,
have never been as rich and varied as those for more con-
ventional proteins. For example, GAGs cannot be trans-
fected into cells, nor can one express dominant negative
versions of them. Antibodies that bind GAGs have been
generated, but ones that block functions have not. Re-
agents that interfere with GAG–protein interactions exist
in the form of GAG-binding peptides and cationic drugs,
but their specificity tends to be poor. Free GAGs can also
be used to interfere with GAG–protein binding, but their
large size and potential to act as protein–protein cross-
linkers make it difficult to draw firm conclusions from
their biological effects. Finally, there are a few drugs that
can be used to interfere with GAG biosynthesis, but each
has at least some problems with efficacy, specificity, and/or
toxicity.
In spite of these hardships, cell biologists studying pro-
teoglycans have managed to make some extraordinary dis-
coveries. In particular, the finding that fibroblast growth
factors (FGFs) require heparan sulfate (HS) for high affin-
ity binding to their receptors stands as a milestone in the
elucidation of HSPG function. Yet, even this simple fact
was not easily established. Despite the well known high af-
finity of FGFs for heparin (a rather heavily modified form
of H5 that, owing its low cost, is widely used for studying
protein–HS interactions) and clear evidence that the most
 
abundant cell surface binding sites for FGFs are HSPGs
(Gospodarowicz et al., 1984; Moscatelli, 1987), most early
studies in this area concluded that HSPGs play no direct
role in FGF–receptor interactions and, instead, relegated
HS to the job of protecting FGFs from denaturation or
proteolysis, or sequestering FGFs in the extracellular ma-
trix (Gospodarowicz and Cheng, 1986; Moscatelli, 1987,
1992). What enabled two groups, working in parallel, to
overturn that view, was the judicious use of methods to in-
terfere with GAG expression: in one case, an inhibitor of
GAG sulfation and an HS-degrading enzyme were used
(Rapraeger et al., 1991); in the other case, it was mutant
cell lines that failed to synthesize HS (Yayon et al., 1991).
Since that time, analogous methods have been used by
others to extend the notion of HS-dependent growth fac-
tor to various other polypeptides, including heparin bind-
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ing EGF-like growth factor, hepatocyte growth factor, and
Wingless (a 
 
Drosophila
 
 member of the Wnt family), to
name just a few (Aviezer and Yayon, 1994; Zioncheck et
al., 1995; Reichsman et al., 1996).
 
In Search of Genetic Insights
 
With HS-deficient cell lines proving to be among the more
useful tools for studying HSPG function in vitro, it did not
escape the notice of researchers that mutations affecting
proteoglycans in intact animals could also be extremely in-
formative, especially with regard to cellular functions that
might be difficult to study in vitro. Yet by mid-1995, al-
though a few mutations had been described that directly
or indirectly affect the major chondroitin/keratan sulfate
proteoglycan of cartilage (Li et al., 1993; Hästbacka et al.,
1994; Watanabe et al., 1994), a general lack of mutations
involving HSPGs—even in the more genetically tractable
organisms, such as 
 
C. elegans
 
 and 
 
Drosophila
 
—was be-
coming disturbingly clear. Are HSPGs simply not very im-
portant? Or are they so important that mutations are diffi-
cult to recover in vivo? Or are the genes that control their
synthesis highly redundant? Fortunately, the wait for an-
swers to these questions was not long, with the first infor-
mative studies beginning in late 1995.
Before reviewing these studies, it is useful to distinguish
between two classes of mutations that affect HSPG ex-
pression. The first involves the enzymes and transporters
required for HS biosynthesis. As illustrated in Fig. 1, at
least 14 biochemical steps contribute to the synthesis of
HS chains. A block at some steps would eliminate HS ex-
pression altogether, whereas at others only subtle changes
in the structure of HS chains would be seen. A second
class of mutations involves the core proteins onto which
HS is synthesized. We now know that most cell surface HS
is carried by syndecans, transmembrane proteins of which
four exist in vertebrates, and glypicans, GPI-anchored
proteins of which at least six occur in vertebrates (Bern-
field et al., 1999). On some cells, HS may also be contrib-
uted by other integral membrane proteins, such as CD44
and betaglycan, which have HS-independent functions as
well. In the extracellular matrix, the major carriers of HS
appear to be perlecan (Iozzo et al., 1994) and agrin (Cole
and Halfter, 1996).
 
Glypicans Pop Up Twice
 
A first glimpse at HSPG function in vivo came in 1995
with the analysis of a 
 
Drosophila
 
 mutant known as 
 
divi-
sion
 
 
 
abnormally
 
 
 
delayed
 
, or 
 
dally
 
 (Nakato et al., 1995).
Mutations in 
 
dally
 
 were identified on the basis of cell divi-
sion patterning defects in the eye and larval brain. In par-
ticular, certain sets of neuronal precursors show a disrup-
tion in progression from the G2 to M phases of the cell
cycle. In the brain, this failure of orderly cell division dis-
rupts a subsequent division cycle that is triggered by pho-
toreceptor axons arriving from the developing eye. Se-
quencing of the 
 
dally
 
 gene revealed that it encodes a
protein belonging to the glypican family of cell surface
HSPGs (Nakato et al., 1995). Biochemical studies have
since shown that Dally bears all the features of vertebrate
glypicans including glycosylphosphoinositol (GPI)–ancho-
rage and selective glycosylation with HS (Jackson et al.,
1997; Tsuda et al., 1999).
The functions of 
 
dally
 
 are not limited to the nervous sys-
tem. Analysis of a collection of mutant alleles showed that
it is required for the proper morphogenesis of other tis-
sues, including the wing, antenna, and genitalia. Further-
more, difficulties in isolating complete loss-of-function
 
dally
 
 alleles suggest that 
 
dally
 
 is a haplolethal locus (Lin
and Perrimon, 1999; Tsuda et al., 1999), i.e., the level of
 
dally
 
 expression is so critical that a reduction to 50% of
the wild-type is lethal.
The initial characterization of 
 
dally
 
 mutants was rapidly
followed by a report that an X-linked human disorder
known as Simpson-Golabi-Behmel syndrome (SGBS) is
caused by deletions and mutations in the gene encoding
glypican-3 (Pilia et al., 1996). SGBS is characterized by
pre- and postnatal overgrowth of multiple tissues and or-
gans, together with an increased susceptibility to the for-
mation of certain tumors.
Is there a common basis for the very different fly and
human phenotypes that result from glypican mutations?
At a very basic level, both phenotypes suggest a derange-
ment of cellular growth control, an interpretation that fits
with the currently popular model that HSPGs are compo-
nents of growth factor signaling pathways. To address this
issue, 
 
dally
 
 was tested for its ability to affect signaling me-
diated by two known HS-binding growth factors in 
 
Dro-
sophila
 
, Decapentaplegic (Dpp), a TGF-
 
b
 
–/bone morpho-
genetic protein–related protein, and Wingless (Wg), a Wnt
family member. The results strongly suggest that Dally po-
tentiates cellular responses to both molecules, but with
surprising tissue specificity. In the embryo, Dally influ-
Figure 1. Pathways in heparan sulfate proteoglycan biosynthesis.
HSPGs are produced by the polymerization of polysaccharide
chains onto serine residues of core proteins, followed by incom-
plete carbohydrate modifications involving sulfation, deacetyla-
tion, and/or epimerization of glucoronic acid residues to iduronic
acid. Additional enzymatic and transport steps are required to
generate the UDP sugars and PAPS (39-phosphoadenosine-59-
phosphosulfate) that participate in many of these reactions (for
review see Lindahl et al., 1998). 
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ences Wg but not Dpp-directed events, whereas in the de-
veloping genitalia 
 
dally
 
 promotes Dpp signaling yet is an-
tagonistic to Wg (Tsuda et al., 1999).
In the case of SGBS, initial attempts to understand the
phenotype focused on the possibility that glypican-3 might
affect signaling by insulin-like growth factors (IGFs). This
idea was suggested by the phenotypic overlap between
SGBS and another overgrowth syndrome, Beckwith-
Wiedemann syndrome. The latter is a complex genetic dis-
order that causes the loss of imprinting, and resultant
overexpression, of the gene encoding IGF-II (Reik and
Maher, 1997). The hypothesis was put forth that loss of
glypican-3 also leads to increased IGF-II expression or ac-
tivity, i.e., that glypican-3 is an endogenous inhibitor of the
growth-promoting effects of IGFs. Indeed, Pilia et al. (1996)
initially asserted that glypican-3 binds directly, via its core
protein, to IGF-II, but subsequent studies contradict that
finding (Song et al., 1997). Instead, the possibility has been
raised that glypican-3 acts more at the level of stimulation
of apoptotic cell death, rather than restraint of cell prolif-
eration. For example, cell culture data show that transfec-
tion of exogenous glypican-3 into certain cell lines can trig-
ger apoptosis (Gonzalez et al., 1998). More recently,
Cano-Gauci et al. (1999) have generated a glypican-3–null
mouse, which replicates some of the features of SGBS. In
these animals alterations in systemic and tissue IGF-II lev-
els are not observed.
 
A Flurry of Mutants in Biosynthetic Enzymes
 
Whereas studies on 
 
dally
 
 and glypican-3 showed that mu-
tations in HSPG core protein genes can have dramatic
phenotypes, recent work on other HSPGs (e.g., syndecan-1,
glypican-2), suggests that loss-of-function phenotypes can
also be subtle or undetectable, most likely because of com-
pensation or functional redundancy among HSPGs (Bern-
field et al., 1999; Saunders, S., and A.D. Lander, un-
published data). One way to circumvent this potential
problem is to study the effects of mutations that alter gly-
cosaminoglycan biosynthesis, since these should presum-
ably affect all HSPGs.
The first descriptions of phenotypes stemming from mu-
tations in glycosaminoglycan biosynthesis came from what
was, at the time, an unexpected quarter: 
 
Drosophila
 
 labo-
ratories searching for new components of the Wg and Dpp
signaling pathways. Three groups simultaneously reported
that 
 
sugarless
 
 (
 
sgl
 
, also known as 
 
supenkasper
 
 or 
 
kiwi
 
), a
gene encoding a protein homologous to vertebrate UDP
glucose dehydrogenase (UDPGDH), is required for Wg-
directed patterning of the early embryo (Binari et al.,
1997; Hacker et al., 1997; Haerry et al., 1997). Mutations in
 
sgl
 
 also suppressed the effects of expressing activated Dpp
receptors in the wing (O’Connor and Haerry, 1999), sug-
gesting a role for 
 
sgl
 
 in Dpp signaling.
UDPGDH is the enzyme that generates UDP-gluc-
uronic acid, which donates the glucuronate that is one of
the two sugars in the repeating disaccharide backbones of
both HS and chondroitin sulfate (Fig. 1). Indirect evidence
that sgl protein indeed has UDPGDH activity comes from
the observation that GAG modification of both D-synde-
can and Dally is disrupted in 
 
sgl
 
 mutants (Haerry et al.,
1997; Tsuda et al., 1999). Interestingly, 
 
sgl
 
 mutants not
 
only have defects in Wg signaling, but also show genetic
interactions with 
 
dally
 
, suggesting that glycosaminogly-
can modification of Dally is critical for its activity in Wg-
directed events (Tsuda et al., 1999).
Whereas UDPGDH generates one of the building
blocks of HS, the enzyme that actually assembles the HS
polymer is the HS copolymerase, so named because bio-
chemical studies suggest that a single protein adds both
glucuronate and 
 
N
 
-acetylglucosamine to growing HS poly-
mers (Lind et al., 1993). Until recently, the molecular
identity of this enzyme was a mystery, but in the last few
years, both its identity and mutant phenotypes in flies and
man have emerged.
An early clue to the identity of the copolymerase came
from somatic cell, rather than animal, genetics. The dis-
covery by Spear and colleagues that the binding of Herpes
viruses to cell-surface HS is a key initial step in viral infec-
tion (Shieh et al., 1992) implied that selection of cultured
cells for viral resistance might allow one to isolate mutants
in HS biosynthesis. Tufaro and colleagues did just this
(Banfield et al., 1995), and, subsequently, used an expres-
sion cloning strategy to identify a cDNA that restored vi-
rus sensitivity to a severely HS-deficient cell line (McCor-
mick et al., 1998). Subsequent biochemical studies showed
that the protein encoded by the cDNA was likely to be all
or part of the HS copolymerase (Lind et al., 1998).
The cDNA isolated by these studies corresponds to
EXT2, one of three tumor suppressor genes that had been
identified by linkage analysis as responsible for the auto-
somal dominant disorder hereditary multiple exostoses.
Apparent loss-of-function mutations in either EXT1 or
EXT2 predispose to the development of benign cartilage-
capped tumors from the growth plates of bones, tumors
that occasionally progress to malignancy (Wuyts et al.,
1998). Like EXT2, EXT1 also can restore HS copoly-
merase activity in deficient cell lines (Lind et al., 1998).
Taken together with the linkage of SGBS to glypican-3
(see above), the data on the EXT genes provide a second
clear connection between disruption of HSPG function,
loss of growth control, and tumor development. For a re-
searcher arguing that HSPGs act as coreceptors for mam-
malian growth factors, these results were reassuring, but
also disquieting in that in vivo data were now pointing to-
ward a role of HSPGs in the restraint, rather than promo-
tion, of cell growth. Whether this reflects a major role for
HS-dependent growth factors in growth inhibition in vivo,
or just an incomplete understanding of how HSPGs affect
growth factors, is unclear.
Help in sorting out this puzzle may have come from the
 
Drosophila
 
 field. At the same time that the connection be-
tween mammalian EXT genes and HS biosynthesis was
made, Bellaiche et al. (1998) described the 
 
Drosophila
 
gene 
 
tout-velu
 
 (
 
ttv
 
). 
 
ttv
 
 encodes an EXT-1 homologue and,
nicely confirming the data on vertebrate EXT genes, 
 
ttv
 
mutants exhibit a great reduction in HS (but not chon-
droitin sulfate) levels (Toyoda et al., 2000). Mutations in
 
ttv
 
 were picked up in a screen for maternally acting genes
affecting early patterning of the embryo (
 
tout-velu
 
 means
all hair, a reference to the appearance of the cuticles of af-
fected embryos). Embryos lacking 
 
ttv
 
 function show seg-
ment polarity defects also found in 
 
wingless
 
 and 
 
hedgehog
 
mutants, although a closer study suggested that 
 
ttv
 
 prima- 
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rily disrupts hedgehog signaling. Hedgehogs are secreted
factors critical for patterning both in flies and vertebrates.
The nature of the defect in 
 
ttv
 
 mutants is intriguing. Evi-
dently, hedgehog protein is made and secreted, and cells
are able to respond to it, but the movement of the protein
through tissue is abnormal. For example, in the developing
wing, hedgehog protein normally travels and acts at a dis-
tance of 8–10-cell dimensions from the site of its pro-
duction. When clones of cells that are mutant for 
 
ttv
 
 are
generated in the field of cells that normally respond to
hedgehog, only those cells directly adjacent to hedgehog-
producing cells receive the signal. Staining for the hedge-
hog protein suggests it is not being transported through
the mutant cells and, indeed, one can observe that wild-
type cells on the other side of the mutant clone are also de-
prived of their hedgehog signal (Bellaiche et al., 1998).
Although hedgehogs are known to bind heparin (Bum-
crot et al., 1995), this implication of HS in hedgehog func-
tion was entirely novel. Interestingly, one of the three ver-
tebrate hedgehogs, Indian hedgehog, is primarily known
as a regulator of bone development, where it acts to limit
chondrocyte differentiation (Vortkamp et al., 1996). It is
tempting to speculate that the cartilaginous overgrowth
associated with the EXT mutations in man is explained, at
least in part, by a disruption of Indian hedgehog function
or localization. Whatever the mechanism, the notion that
HS plays a major role in cartilage development is becom-
ing increasingly apparent, as was most recently—and un-
expectedly—driven home by the finding that abnormali-
ties in cartilage growth are among the most obvious
phenotypes resulting from targeted deletion of the mouse
gene for the HSPG perlecan (Costell et al., 1999).
 
The Finer Points of Fine Structure
 
Enzymes like UDPGDH and the HS copolymerase are re-
quired to generate HS chains altogether. Many enzymes in
the HS biosynthetic pathway, however, function down-
stream of these to modify HS, generating patterns of sulfa-
tion and sugar isomerization known as fine structure.
There is evidence that these modifying enzymes act se-
quentially, with early steps required for later ones to pro-
ceed (Lindahl et al., 1998). The earliest such modification
transforms blocks of 
 
N
 
-acetylglucosamine residues into
 
N
 
-sulfoglucosamine. At least three different, but homolo-
gous deacetylase/sulfotransferase enzymes, can carry out
this function in mammalian cells. However, in 
 
Drosophila
 
,
a single homologue is known. Like the UDPGDH homo-
logue 
 
sgl
 
, it was recovered from a screen for mutations
that disrupt wingless signaling, and it has been named 
 
sul-
fateless
 
 
 
(sfl) 
 
(Lin and Perrimon, 1999).
Curiously, in 
 
sfl
 
 mutants Dally molecules carry reduced
amounts of HS, rather than just HS that is less sulfated
(Lin and Perrimon, 1999), a result that suggests some sort
of feedback regulation of HS polymerization. Regardless,
the 
 
dally
 
, 
 
sgl
 
, and 
 
sfl
 
 phenotypes all strongly point to a crit-
ical role for HSPGs in Wingless signaling.
What about fine structure modifications downstream of
 
N
 
-sulfation? So far the only step at which mutant pheno-
types have emerged is the 2-O-sulfation of uronic acid res-
idues (Fig. 1). And once again, flies and mammals have
taken center stage almost simultaneously.
On the mammalian side, Bullock et al. (1998) recently
described the phenotype of a gene-trap mutation in mice
that disrupts the only known HS 2-O-sulfotransferase.
These animals exhibit absent kidneys, abnormalities of the
skeleton and eye, and perinatal death. Kidney develop-
ment arrests at a relatively early stage, in which mesen-
chyme condenses around the ureteric bud and branching
morphogenesis begins. Although the factors involved in
kidney morphogenesis are numerous, they include multi-
ple HS-binding growth factors, especially Wnts (Kispert
et al., 1998).
On the 
 
Drosophila
 
 side, Sen et al. (1998) reported that
the product of the 
 
pipe
 
 gene is a homologue of the mam-
malian HS 2-O-sulfotransferase. 
 
Pipe
 
 is a gene involved in
setting up dorsal-ventral polarity in the 
 
Drosophila
 
 em-
bryo. It is expressed in the ventral follicle cells of the
ovary, where it is required for the proteolytic activation of
the secreted protein, Spätzle, which occurs after egg depo-
sition. Active Spätzle engages a receptor in the plasma
membrane of the early embryo, establishing a nuclear dor-
sal-ventral gradient of the NF-
 
k
 
B/Rel–like transcription
factor, Dorsal. 
 
pipe
 
 is not only necessary for directing a
ventral fate, but also sufficient, since misexpression of
Pipe in dorsal follicle cells produces a completely ventral-
ized embryo.
Assuming Pipe does encode an HS 2-O-sulfotransferase
(which has yet to be established), these findings suggest
that a spatially localized HSPG controls the proteolytic ac-
tivation of a growth factor. Such a mechanism recalls the
well studied role of heparin and HS in the regulation of
proteolysis by thrombin (although, in the case of thrombin
the role of HS is to accelerate inhibition, rather than acti-
vation, of the protease [Olson and Björk, 1992]).
 
New Questions, New Models
 
The genetic experiments described above have provided a
bountiful harvest of exciting information. Clearly HSPGs
are key players in development. Clearly they influence
cell–cell signaling and morphogenesis. Yet each answer
provokes new questions and raises new cautions.
Perhaps the most important question right now con-
cerns the mechanisms of action of HSPGs. In vitro studies
have suggested that some growth factors require HSPGs
as coreceptors to bind to, or signal at, their receptors.
 
Drosophila
 
 Wg appears to fall into this category (Reichs-
man et al., 1996), which is likely to explain the effects of
 
dally
 
, 
 
sgl
 
, and 
 
sfl
 
 mutations on Wg function in vivo. FGFs
are thought of as the quintessential HS-dependent growth
factors, and it is indeed comforting to know that further
study of 
 
sgl
 
 and 
 
sfl
 
 mutants has shown clear defects in FGF
receptor signaling (Lin and Perrimon, 1999).
In contrast, the evidence that HSPGs potentiate Dpp
signaling, obtained from the study of 
 
dally
 
 and 
 
sgl
 
 mu-
tants, comes as a surprise to those laboring in vitro, whose
work has suggested that interactions with HS, if anything,
inhibit the functions of BMP2, a mammalian orthologue of
Dpp (Ruppert et al., 1996). Researchers are also at a loss
for an HS-stimulated growth-inhibitory signaling pathway
onto which to pin the abnormalities of SGBS. Whereas it
is certainly possible that HS dependence in the activities of
certain growth factors has been missed until now, the 
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rather sharp tissue specificity of several HS mutant phe-
notypes (e.g., mammalian 2-O-sulfotransferase), together
with the curiously tissue-specific effects of 
 
dally
 
 (see
above) suggest that HS dependence is a phenomenon that
may be context dependent. To accommodate this idea,
simple models such as promotion of growth factor dimer-
ization, or increasing local growth factor concentration by
HS, may need to be extended and/or modified (Lander,
1999).
Similarly, the stunning and unexpected defects in
Hedgehog transport in 
 
ttv
 
 mutants also suggest that new
thinking about mechanism is called for. Until recently,
much has been said about the ability of PGs to arrest or
slow the diffusion of ligands, with only a few suggestions
that they might accelerate it (Lander, 1998). One possibil-
ity is that in the developing fly wing, HSPGs are released
from cells in soluble form and, in binding Hedgehog, in-
hibit its interaction with other cell-surface or extracellular
binding sites, thereby allowing it to diffuse more freely.
That HSPGs are efficiently shed from mammalian cells
has been well established (Bernfield et al., 1999). Another
possibility is that HSPGs affect Hedgehog transport indi-
rectly, by affecting Hedgehog proteolytic processing or
cholesterol modification in a manner as yet unknown (but
perhaps analogous to their role in processing of Spätzle).
A third possibility is that movement of Hedgehog through
tissues is not mediated by diffusion at all but by a vesicular
transcellular transport, such as has been suggested for Wg
(Gumbiner, 1998). To this end, it is interesting that HSPGs
have been observed to mediate internalization of proteins
through highly specific mechanisms (Reiland and Raprae-
ger, 1993). Alternatively, the fact that one family of
HSPGs is GPI-anchored raises the additional possibility of
movements of HSPG-attached Hedgehog by direct parti-
tioning of GPI-anchored proteins from one plasma mem-
brane into another (Kooyman et al., 1995).
 
Coming Attractions
 
The in vivo data of the last few years are having a dramatic
impact on the way proteoglycans are viewed by biologists.
In response, we are likely to see renewed and expanded ef-
forts by biochemists and cell biologists to address the criti-
cal mechanistic questions raised above. In addition, it is
important to remember that we have only seen the first
wave of animal data on proteoglycans. For genes that have
essential functions throughout life, early genetic studies
invariably highlight developmental roles since develop-
mental phenotypes often prevent adulthood from being
reached. Pinning down the adult functions of HSPGs
through genetic means will require more effort, but is fea-
sible. Given the intriguing data over the years that have
linked HSPGs to cell adhesion (LeBaron et al., 1988),
wound healing (Bernfield et al., 1999), microbial invasion
(van Putten and Paul, 1995), viral infection (Shieh et al.,
1992), lipoprotein metabolism (Ji et al., 1997), and cancer
(Kleef et al., 1998), it is likely that such an effort would be
handsomely rewarded.
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